AcuCort will participate at the Biotech International Convention, which takes place in Boston, USA, from June 5 to June 8, 2023.
The Biotech International Convention is the world’s largest meeting place for pharmaceutical and biotechnology companies, where opportunities are provided for cooperation and partner discussions as well as investor meetings. In total, over 8,000 companies participate in the event.
“The USA is a large and important market for AcuCort, therefore this event is of great importance for establishing contacts and meeting potential partners for the US market”, says Jonas Jönmark, CEO of AcuCort.
For further information please contact:
Jonas Jönmark, vd, AcuCort AB
Telefon: 070 365 5400
Epost: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark, Norway and Finland. All in all, it strengthens the company’s assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.